FDA to require new trials for COVID-19 boosters for under-65s

EditorLouis Juricic
Published 05/20/2025, 11:13 AM
© Reuters.

Investing.com -- The U.S. Food and Drug Administration (FDA) has announced plans to mandate fresh clinical trials for the approval of annual COVID-19 booster shots for healthy Americans under 65. Consequently, the availability of these boosters will be primarily restricted to older adults and individuals at a higher risk of severe illness this fall, according to FDA leaders on Tuesday.

FDA Commissioner Marty Makary and top U.S. vaccines regulator Vinay Prasad predict that the FDA will approve the boosters for adults over the age of 65 based on immune response data from patient tests. The boosters will also be available for all individuals over six months old who possess one or more risk factors that increase their chances of severe COVID-19 outcomes. This information was published in the New England Journal of Medicine on Tuesday.

However, for healthy individuals aged between six months and 64 years, the FDA expects drugmakers to conduct randomized, controlled trials to obtain approval for annual shots. In these trials, saline could serve as a placebo, as stated by Prasad and Makary.

Vaccine manufacturers have argued that annual modifications to COVID vaccines to match the current virus strain could result in new placebo-controlled trials delaying the availability of the shots until after their effectiveness has expired.

Prasad and Makary, however, believe these studies are essential to verify that annual shots for healthy younger Americans are evidence-based. They argue that without these studies, it’s unclear whether a healthy 52-year-old woman who has had COVID-19 three times and has received six previous COVID-19 vaccine doses will benefit from a seventh.

Currently, there are three approved COVID-19 vaccines in the U.S.: Moderna Inc (BMV:MRNA)’s and Pfizer-BioNTech’s messenger RNA-based shots, and a protein-based vaccine by Novavax (NASDAQ:NVAX) Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.